Group items tagged

The National Pharmacy Association (NPA) has called on the NHS England to uplift funding for pharmacy contractors to enable them to cover higher staffing costs along with a range of other cost-inflating factors. This follows latest data released by the recruitment platform Locate a Locum, which showed a huge increase in locum rates for pharmacists in 2021 and predicted the trend to continue. The report noted a 71 per cent surge in the cost of employing locum pharmacists in England, from the 2020 average to the second half of 2021. NPA chief executive Mark Lyonette said: "There is a heavy reliance on locums in community pharmacy to maintain continuity of services with the average pharmacy operating 50 hours per week. Consequently, increases in locum rates have a big effect on the cost base. "Pharmacies face a range of general cost pressures beyond locum rates, including much higher energy costs. We hear a lot about the cost of living crisis; our members are facing a cost of doing business crisis and it's every bit as real. "The underlying underfunding, significant general inflationary pressures and specific cost increases relating to the locum workforce together make a powerful and urgent case for new funding."

Community pharmacists across the UK are looking for ways to reduce operational costs and find new sources of revenue. This is a pressing issue for the sector: reversing a decade of cuts to pharmacy funding will be a mammoth task, while pharmacists have taken on new primary care responsibilities under Pharmacy First. This means that fresh sources of revenue and lower costs will overwhelmingly come from new technology and the efficiencies they can bring. As Britain's 11,500 community pharmacies assume a larger role on the frontlines of primary care, pharmacists should rapidly implement cost-effective tech solutions that provide pharmacies with a one-stop-shop to drive down costs and increase revenue. Opportunity in PGD reform New technology will be key for community pharmacists to benefit fully from reforms to PGDs. The scope of PGDs is now significantly expanding: as of June 26, pharmacy technicians are now on the list of registered healthcare professionals who can make use of PGDs. These reforms can benefit community pharmacies in several ways. For one, they will allow more pharmacy staff to administer 'frontline services' such as vaccinations - reducing costs and generating revenue. Further, the wider range of services that pharmacies can offer under Pharmacy First will make these procedures, as well as other kinds of preventative care, more accessible and convenient - increasing footfall. With international travel and tourism now growing apace, increased demand for travel vaccinations means that, according to research from Charac, the average UK community pharmacy can expect to generate £46,800 a year through travel health services.

The loss of a foot or limb due to landmine explosions or any disease is a major tragedy for any human being and to come to terms with this loss of a part of the body is not only a very traumatic experience but also fraught with dire economic consequences. A financially independent person suddenly realizes that he or she is totally at the mercy of relatives and friends and unable to indulge in any income generating activity. Prospects of poverty loom large over the horizon and this mental anguish coupled with the physical injury can wreck many a life.Buy online Handicapped Tricycle and disabled at lowest price and cheap cost in india from wheelchair india online shopping store of Tricycle manufacturer, distributor, dealer and supplier of variety of Tricycles at low price in india for handicapped Rehabilitation of such individuals is of prime importance and it is here that Help Handicapped International (HHI) plays a pivotal role especially in conflict areas where the number of landmine amputees is large. HHI is a registered charity working for the welfare of the physically handicapped and an NGO in special consultative status with ECOSOC. HHI specializes in fitting the Jaipur Foot prosthetic-an artificial limb developed in India and the most preferred in Asia and Africa because of the following factors: (i) It is light in weight (ii) It is fast and easy to fabricate. Since its manufacturing takes only a few hours the patient who comes to the centre in the morning can walk out on his own artificial limb by evening. (iii) It is very cost effective. (iv) It facilitates cycling, walking bare foot and squatting-all tasks essential to lead a near normal life in these continents. Post fitment the patient undergoes physiotherapy sessions to become accustomed to the artificial limb. He or she is also explained about some simple exercises that could be carried out at home as well as some tips on the proper use and maintenance of the prosthetic. HHI has b

The proposed increase in the national living wage (NLW) is expected to impose an implementation cost of £150 million to £195 million on the community pharmacy sector, Community Pharmacy England (CPE) has warned. Chancellor Jeremy Hunt recently announced a 9.8 per cent increase in the national living wage, raising it from £10.42 to £11.44. "The Autumn Statement overlooks the knock-on effects these measures will have on small businesses like community pharmacies," CPE Chief Executive Janet Morrison said in a statement. "The majority of pharmacies employ staff on or around the NLW, which has increased nearly 40 per cent since the start of the current contractual framework." "This is at a time when pharmacies have faced a 30 per cent real terms reduction in funding since 2015," Morrison added. "No viable business can absorb these cost increases without significant support. This is just another cost pressure that pharmacies cannot control and must be addressed through a sustainable, long-term funding arrangement."

Yes, India is well-regarded for eye surgery, offering a combination of advanced medical facilities, highly skilled ophthalmologists, and cost-effective treatments. Here are some reasons why India is considered a good destination for eye surgery: 1. Advanced Medical Facilities 2. Experienced Ophthalmologists 3. Cost Effective Treatment 4. Availability of Specialized Treatments 5. No Waiting Time 6. Medical Tourism Support

The National Institute for Health and Care Excellence (NICE) has issued draft guidance on 'Evusheld' which is not recommended for vulnerable adult with high risk of severe Covid-19 on Thursday (16 February). The draft guidance is open for public consultation until 9 March 2023. The committee will consider any comments received at a meeting currently due to take place on 4 April 2023. It comes after last month's decision by the US drug regulator to withdraw its emergency use authorisation for Evusheld as a preventative treatment for Covid-19, which said there was insufficient evidence that Evusheld is effective against the dominant variants of Covid-19 in the US. NICE's independent appraisal committee has reached the same conclusion having considered evidence which shows Evusheld is unlikely to prevent infection with most of the variants circulating in the UK now and in the near future. It has also announced that it is developing a new review process to update recommendations on the cost-effectiveness of Covid-19 treatments so they can be made available more quickly to patients if they show promise against new variants and are found to be cost-effective.

The decision to consider minimum cost of heart valve replacement surgery in India during the Christmas season of 2024 is driven by several compelling factors. India has emerged as a leading destination for medical tourism, particularly in the field of cardiac surgery.

The minimum cost for Ventricular Septal Defect (VSD) surgery in India starts at approximately $4,000 USD, significantly lower compared to many countries. These cost-effective packages include expert surgical care, pre-surgery diagnostics, hospital stay, and basic medications.

The General Pharmaceutical Council (GPhC) has decided to increase the renewal fees of pharmacists, pharmacy technicians, and pharmacy premises by 7.5% from April 2024. The pharmacy technician's renewal fee will see an increase by £9 from £121 to £130, pharmacists fees from £257 to £276, and pharmacy premises from £365 to £392. The following decision came even despite the renewal fees being frozen for individual registrants since 2019 and for pharmacy premises since 2021. This move was facilitated through cost savings measures like using financial reserves and downsizing to a smaller office. However, the council confirmed that the fee hike is due to higher rates of inflation, increase in utility bills and supplier costs. Duncan Rudkin, Chief Executive and Registrar of the GPhC, said: "We know that these are challenging times and that this increase will come as unwelcome news to those we regulate. But to be effective in our role of protecting the public we need to make sure the fees we charge cover the cost of regulation going forward."

Cerebral palsy (CP) is a group of conditions caused by medical abnormalities in the development of a fetus or the early life of a child. These lead to damage or delayed development in the brain. The disorder is permanent and, though it does not worsen with age, the level of functionality of a person with cerebral palsy varies widely: in some cases, effects may be very minor, while in others, movement is impaired to the extent that a wheelchair is required. Common complications associated with CP vary by the type of CP disorder but can include vision problems, seizures, learning disabilities, and issues speaking, writing, and performing other tasks related to motor control. Cerebral palsy is the focus of a large amount of medical research every year. Though much of this research deals with younger patients, more and more attention is being paid to CP sufferers as they age and seek fuller opportunities and more integration with the rest of society. Living with CP is a daily challenge, but paths to a richer and more fulfilling life are being found. There is not, and may never be a "cure" for CP, but greater understanding by clinicians and the daily success stories of those who overcome their limitations are making. Buy online CP Wheelchair, Pediatric Cerebral Palsy Wheelchair, Cerebral Palsy Wheelchair, CP Child Wheelchair for handicapped and disabled at lowest price and cheap cost in india from wheelchair india online shopping store of Karma CP Wheelchair, Pediatric Wheelchair, Cerebral Palsy Wheelchair, CP Child Wheelchair at low price in india. Causes of Cerebral Palsy Cerebral palsy is generally caused by developmental issues during pregnancy which lead to abnormal conditions in the brain. During the birth process, lack of oxygen caused by premature delivery or delivery-room errors can cause brain damage that facilitates cerebral palsy. Cerebral palsy can also be caused by recognizable brain injuries sustained by the developing child up to an early

Dental procedures are a necessary evil for most people. We all know that we need to go in for a cleaning and check-up at least once a year, but sometimes the cost of these procedures can be prohibitive. It's hard to know which procedures are worth the money and which ones aren't. Here is an essential list of dental procedures that are worth the money. CAVITY FILLINGS Cavities are caused by tooth decay. If left untreated, cavities can cause severe damage to your teeth. They can also lead to pain and infection. The best way to treat a cavity is to have it filled by a dentist. During the procedure, your dentist will remove the decay from your tooth and then fill the cavity with a composite material. This material is solid and durable and can help restore your tooth to its original shape and function. Modern materials and techniques have made cavity fillings much more effective than they used to be. Most fillings last for many years with proper care. ROOT CANALS It's a dental procedure that is used to treat an infected tooth. During the procedure, the dentist will remove the infected tissue from the tooth and then fill the space with a particular material. The procedures are very effective in treating infected teeth. They can also help to prevent the spread of infection to other teeth. Root canals are usually very successful, and most teeth with a root canal can last for many years. Generally, the cost of the procedure will depend on the severity of the infection and the number of teeth that need to be treated. If you are considering treatment for a root canal, it is crucial to find a qualified and experienced dentist who has experience. You want a team that assures you of world-class standards in all their procedures. This is what brings you value for your money.

The National Institute for Health and Care Excellence (NICE) has recommended Enhertu for people with advance breast cancer. "There is not enough evidence yet to show how much longer people live with Enhertu compared with trastuzumab emtansine because the clinical trial is still ongoing. This means the cost-effectiveness estimates are highly uncertain and Enhertu cannot be recommended for routine use in the NHS," said NICE. The independent appraisal committee concluded that Enhertu could be cost-effective if further evidence from the ongoing trial and from NHS practice can show how much longer people live with treatment. Helen Knight, director of medicines evaluation at NICE, said: "Today's draft guidance is good news for people with this type of advanced breast cancer, who often experience severe and debilitating symptoms.

The Department of Health and Social Care (DHSC) has announced 30 pence increase in prescription charges from £9.35 to £9.65 for each medicine or appliance dispensed. Board Chair for England at RPS, Thorrun Govind commented: "This is a kick in the teeth for people in England who are already struggling with rising bills and food prices. "Patients groups have warned that people are not collecting prescription medicines due to cost and pharmacists are seeing this worrying trend first-hand. "A Government impact assessment noted the risk of adverse effects of people not taking their medicines, resulting in future health problems for the individual, potential hospital admissions, and a subsequent cost to the NHS. "This decision seems to prioritise revenue generation over ill-health prevention and undermines the principle of an NHS free at the point of use.

A PAGB report has emphasised the need to empower the public to practice self-care and improve access to over-the-counter (OTC) medicines to alleviate pressure on GPs and reduce NHS costs. Launched at the Labour Party Conference today, the PAGB's State of the Nation report explores the current state of self-care and OTC medicines. The report outlines 11 recommendations for the government to consider as part of its strategy to build an NHS fit for the future. It highlights that each year, at least 25 million GP appointments and 5 million A&E visits are used for self-treatable illnesses, which can be effectively managed through self-care. The report suggests that empowering individuals to utilise OTC medicines could save the NHS at least £1.7 billion per year in costs. Furthermore, it says that eliminating these appointments could save the economy an additional £350m per year, as employees would not need to take time off work for unnecessary treatments. PAGB welcomed the government's manifesto commitments to take pressure off GP surgeries by "improving access to services and treatment through new routes" and to expand the role of pharmacists.

The MHRA on Wednesday granted a license for Eli Lilly's new Alzheimer's treatment, donanemab, for use in adults with mild cognitive impairment or mild dementia due to Alzheimer's disease. However, the drug will not be available on the NHS, as the National Institute for Health and Care Excellence (NICE) concluded that it "does not currently demonstrate value for the NHS." The health spending watchdog explained that the costs of providing donanemab, including regular infusions and intensive monitoring for serious side effects, outweigh the relatively small benefits it offers to patients, and so it "cannot currently be considered good value for the taxpayer." Helen Knight, director of medicines evaluation at NICE, said: "For NICE to be able to approve a medicine for use in the NHS it must provide additional benefits to patients, and it must also represent a good use of NHS resources and taxpayers' money. Donanemab (also called Kisunla) is a monoclonal antibody drug given by infusion (through a drip in the arm). It targets and reduces beta-amyloid proteins, whose abnormal buildup is associated with Alzheimer's disease. Clinical trial evidence suggests that the monthly injection can slow Alzheimer's disease progression by 4 to 7 months.

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug. The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165 per cent over the past two years. The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new data could lead the U.S. government to reassess that.

The Pharmaceutical Society NI (PSNI)'s Council has decided to freeze the annual registration fee for the current financial year 2023/24. The annual registration fee is considered each year by the PSNI's council. At its meeting in November 2022, Council members in recognition of the effects of the Covid-19 pandemic, the personal and professional impact of the cost of living crisis on pharmacists, and the overall cost of regulation agreed to maintain registration fees at their current level for the next financial year. Pharmaceutical Society NI's Chief Executive Michaela McAleer said: "I am pleased with Council's decision to continue the freeze on registration fees for the 7th successive year. We are acutely aware of the pressures facing the pharmacy profession and hope this can provide some reassurance to the profession as we deal with these financially difficult times.